TRAZER ® is an Itraconazole-based drug
THERAPEUTIC GROUP: Antifungals for systemic use - triazole derivatives
Indications TRAZER ® Itraconazole
TRAZER ® is indicated in the treatment of both superficial and systemic fungal infections sustained by fungi, yeasts, dermatophytes and microorganisms sensitive to Itraconazole.
Mechanism of action TRAZER ® Itraconazole
Itraconazole, active ingredient of TRAZER ®, is an antifungal drug effective against a great many dermatophytes, yeasts, fungi and various microorganisms, therefore characterized by a broad spectrum of action which guarantees an important extension of clinical applications.
The cytostatic and sometimes cytotoxic activity is determined by the ability of Itraconazole to inhibit the enzymatic pathway that leads to the synthesis of ergosterol, a key element of the microorganism's plasma membrane, the presence of which gives the structure rigidity and resistance, guaranteeing its correct functionality and vitality. .
At the same time, the inhibition of this pathway determines an increase in the concentrations of numerous catabolites, the presence of which interferes with the normal functioning of the membrane transporters, thus inducing the death of the microorganism due to the absence of pro-energetic pathways.
The clinical efficacy of this drug is also supported by the excellent pharmacokinetic properties, which allow the Itraconazole taken orally to reach its plasma peak within the first 5 hours of taking.
Well distributed to all tissues and partly metabolised by cytochromial enzymes, Itraconazole is eliminated both unchanged via urine and faeces and by the normal skin desquamation process.
Studies carried out and clinical efficacy
L "ITRACONAZOLE IN SEBORROIC DERMATITIS
Postepy Hig Med Dosw (Online). 2012 Nov 14; 66: 848-54.
Investigations of seborrheic dermatitis. Part II. Influence of itraconazole on the clinical condition and the level of selected cytokines in seborrheic dermatitis.
Trznadel-Grodzka E, BÅ‚aszkowski M, Rotsztejn H.
Very interesting study that tests the efficacy and the molecular mechanism of action of Itraconazole in seborrheic dermatitis. The results in addition to demonstrating an improvement in the clinical condition also observe a significant reduction in blood concentrations of inflammatory cytokines.
THE ANTI-CANCER EFFECT OF ITRACONAZOLE
Oncologist. 2013 Jan 22.
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA.
Experimental study that tests the ability of Itraconazole to inhibit angiogenesis in rheumatoid arthritis. The results, which clearly must be further investigated by appropriate clinical trials, show however a significant reduction in blood concentrations of VEGF, a growth factor involved in the development of new vessels.
THE ITRACONAZOLE IN THE TREATMENT OF ASPERGILLOSIS
J Infect Chemother. 2012 Jun; 18: 378-85.
Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study.
Yoshida K, Kurashima A, Kamei K, Oritsu M, Ando T, Yamamoto T, Niki Y.
Complex clinical trial evaluating the efficacy of short- and long-term treatment with Itraconazole during diseases such as chronic pulmonary necrotizing aspergillosis. Oral or injective use seems to guarantee an improvement in the clinical condition in the long term.
Method of use and dosage
TRAZER ®
Itraconazole 100 mg hard capsules for oral use.
The treatment of both skin and systemic fungal infections with TRAZER ®, must be defined by a doctor based on the physio-pathological characteristics of the patient and the severity of his clinical picture.
For these reasons, therefore, the duration of therapy can vary significantly from case to case.
In any case, however, it is recommended to take the capsule on a full stomach to facilitate the absorption of the active ingredient.
Warnings TRAZER ® Itraconazole
The potential side effects induced by Itraconazole, the complexity of the definition of the therapeutic scheme and the importance in itself of the therapy require the need for a careful medical examination before the start of therapy, in order to identify any conditions that are incompatible or potentially dangerous with the therapy. "taking the drug.
Therefore, patients suffering from hepatic, renal and cardiac diseases should define with their doctor the cost-benefit ratio of therapy with Itraconazole, and possibly undertake therapy under close medical supervision.
The presence of sugars among the excipients of TRAZER ® would expose the patient with lactase enzyme deficiency, glucose-galactose malabsorption syndrome, fructose intolerance and sucrase-isomaltase insufficiency to unpleasant side effects.
It is recommended to store the drug in a cool, dry place out of the reach of children
PREGNANCY AND BREASTFEEDING
The use of TRAZER ® in pregnancy and during breastfeeding is generally contraindicated due to the potential side effects of Itraconazole on the fetus and infant, as shown by the numerous studies in the literature conducted mostly on laboratory animals.
Interactions
The complex hepatic metabolism of Itraconazole, which involves cytochromial enzymes such as CYP3A4 normally responsible for the metabolism of other drugs, exposes the patient receiving TRAZER ® to the risk of potentially dangerous drug interactions.
Therefore, in the event that the need arises to undertake a drug therapy at the same time as that with Itraconazole, it would be advisable to immediately consult your doctor.
There are many active ingredients metabolized by cytochromial enzymes, whose pharmacokinetic characteristics could be compromised by the simultaneous use of Itraconazole.
At the same time, the intake of drugs capable of reducing gastric acidity could compromise the normal absorption of Itraconazole taken orally.
Contraindications TRAZER ® Itraconazole
The use of TRAZER ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients, in patients simultaneously undergoing drug therapy with active substances metabolised by the cytochromial system and in patients with severe hepatic, renal and cardiac insufficiency.
Undesirable Effects - Side Effects
The oral intake of Itraconazole could cause the onset of gastrointestinal disorders such as nausea, diarrhea, vomiting, dyspepsia and flatulence and skin disorders such as rash or eczema.
The side effects described for other organs and systems are much rarer.
Note
TRAZER ® is a prescription drug.
The information on TRAZER ® Itraconazole published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
